Pfizer's Late-Stage Lung Cancer Drug Trial Misses Primary Endpoint
PFE is trading near its 52-week low of $23.11 (6.7% above the low).
Summary
Pfizer's Phase 3 trial for its lung cancer drug, sigvotatug vedotin, failed to meet its primary endpoint of statistically significant improvement in overall survival for non-squamous non-small cell lung cancer. This is a setback for the company's oncology pipeline, contrasting with recent positive news regarding other drug trials and strong financial performance. While the drug showed strong efficacy in a subset of patients and a manageable safety profile, this specific indication is now in question. Pfizer continues to test the drug in a separate first-line treatment trial.
At the time of this announcement, PFE was trading at $24.65 on NYSE in the Life Sciences sector, with a market capitalization of approximately $142.9B. The 52-week trading range was $23.11 to $28.75. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.